The charts on this page feature a breakdown of the total annual pay for the top executives at ALEXION PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ALEXION PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ALEXION PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Paul Clancy
Executive Vice President, Senior Advisor and Former Chief Financial Officer
Total Cash $1,978,218 Equity $3,863,694 Other $23,832 Total Compensation $5,865,744
Ludwig Hantson
Chief Executive Officer
Total Cash $3,680,000 Equity $15,243,634 Other $24,350 Total Compensation $18,947,984
Brian Goff
Executive Vice President, Chief Commercial and Global Operations Officer
Total Cash $1,663,076 Equity $3,863,694 Other $20,240 Total Compensation $5,547,010
John Orloff
Executive Vice President, Head of Research and Development
Total Cash $1,730,498 Equity $3,863,694 Other $32,550 Total Compensation $5,626,742
Anne-Marie Law
Executive Vice President, Chief Human Experience Officer
Total Cash $1,483,130 Equity $3,622,303 Other $33,528 Total Compensation $5,138,961
Aradhana Sarin
Executive Vice President, Chief Financial Officer
Total Cash $1,464,775 Equity $3,380,763 Other $31,604 Total Compensation $4,877,142
For its 2019 fiscal year, ALEXION PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Ludwig Hantson CEO Pay $18,947,984 Median Employee Pay $237,151 CEO Pay Ratio 80:1
For its 2019 fiscal year, ALEXION PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Andreas Rummelt Total Cash $445,046
Christopher Coughlin Total Cash $630,108
David Brennan Total Cash $595,052
Deborah Dunsire Total Cash $445,069
Felix Baker Total Cash $470,046
Francois Nader Total Cash $445,046
John Mollen Total Cash $470,046
Judy Reinsdorf Total Cash $470,013
Paul Friedman Total Cash $445,046

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.